Cargando…

Validation of Cell-Free DNA Collection Tubes for Determination of EGFR Mutation Status in Liquid Biopsy from NSCLC Patients

INTRODUCTION: Precision medicine has revolutionized the understanding and treatment of cancer by identifying subsets of patients who are amenable to specific treatments according to their molecular characteristics, as exemplified by epidermal growth factor receptor (EGFR) mutations in non-small cell...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sesé, Marta, Somoza, Rosa, Maestu, Inmaculada, Ureste, Maria Martín, Sanchez, Alfredo, Cordoba, Juan Felipe, Sansano, Irene, Venturas, Griselda, Ramón y Cajal, Santiago, Hernández-Losa, Javier
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7360002/ https://www.ncbi.nlm.nih.gov/pubmed/32699985 http://dx.doi.org/10.1007/s40487-019-00099-9

Ejemplares similares

The umbilical cord, preeclampsia and the VEGF family
por: Olaya-C, Mercedes, et al.
Publicado: (2018)

Cognitive impairment is related to a reduced count of T-lymphocytes in older patients diagnosed with non-small cell lung cancer (NSCLC)
por: Soria-Comes, Teresa, et al.
Publicado: (2020)

Phosphorylation of eIF4E Confers Resistance to Cellular Stress and DNA-Damaging Agents through an Interaction with 4E-T: A Rationale for Novel Therapeutic Approaches
por: Martínez, Alba, et al.
Publicado: (2015)

Use of liquid biopsy in monitoring therapeutic resistance in EGFR oncogene addicted NSCLC
por: Iacovino, Marialucia, et al.
Publicado: (2020)

Insight into the Role and Regulation of Gap Junction Genes in Lung Cancer and Identification of Nuclear Cx43 as a Putative Biomarker of Poor Prognosis
por: Aasen, Trond, et al.
Publicado: (2019)

Future Perspectives in Detecting EGFR and ALK Gene Alterations in Liquid Biopsies of Patients with NSCLC
por: Ferreira, Daniela, et al.
Publicado: (2021)

Clinical implications of intratumor heterogeneity: challenges and opportunities
por: Ramón y Cajal, Santiago, et al.
Publicado: (2020)

Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain
por: Arriola, Edurne, et al.
Publicado: (2018)

Internal translation of the connexin 43 transcript
por: Salat-Canela, Clàudia, et al.
Publicado: (2014)

Can Liquid Biopsy Based on ctDNA/cfDNA Replace Tissue Biopsy for the Precision Treatment of EGFR-Mutated NSCLC?
por: Li, Yi-Ze, et al.
Publicado: (2023)

Understanding the Mechanisms of Resistance in EGFR-Positive NSCLC: From Tissue to Liquid Biopsy to Guide Treatment Strategy
por: Del Re, Marzia, et al.
Publicado: (2019)

Balance between MKK6 and MKK3 Mediates p38 MAPK Associated Resistance to Cisplatin in NSCLC
por: Galan-Moya, Eva M., et al.
Publicado: (2011)

Unexpected responses to EGFR inhibition in NSCLC
por: Stella, Giulia M., et al.
Publicado: (2015)

Epithelial-Mesenchymal Transition Markers and HER3 Expression Are Predictors of Elisidepsin Treatment Response in Breast and Pancreatic Cancer Cell Lines
por: Teixidó, Cristina, et al.
Publicado: (2013)

Performance of Streck cfDNA Blood Collection Tubes for Liquid Biopsy Testing
por: Medina Diaz, Inga, et al.
Publicado: (2016)

The Impact of Variant Allele Frequency in EGFR Mutated NSCLC Patients on Targeted Therapy
por: Friedlaender, Alex, et al.
Publicado: (2021)

Validation and comparison of two NGS assays for the detection of EGFR T790M resistance mutation in liquid biopsies of NSCLC patients
por: Vollbrecht, Claudia, et al.
Publicado: (2018)

Extracellular Vesicle-Based Bronchoalveolar Lavage Fluid Liquid Biopsy for EGFR Mutation Testing in Advanced Non-Squamous NSCLC
por: Kim, In Ae, et al.
Publicado: (2022)

Sulforaphane attenuates EGFR signaling in NSCLC cells
por: Chen, Chi-Yuan, et al.
Publicado: (2015)

EGFR-Targeted Therapeutics: Focus on SCCHN and NSCLC
por: Sattler, Martin, et al.
Publicado: (2008)

Liquid-Biopsy-Based Identification of EGFR T790M Mutation-Mediated Resistance to Afatinib Treatment in Patients with Advanced EGFR Mutation-Positive NSCLC, and Subsequent Response to Osimertinib
por: Hochmair, Maximilian J., et al.
Publicado: (2018)

Discovery of a novel EGFR ligand DPBA that degrades EGFR and suppresses EGFR-positive NSCLC growth
por: Yao, Nan, et al.
Publicado: (2020)

Liquid Biopsy: A Multi-Parametric Analysis of Mutation Status, Circulating Tumor Cells and Inflammatory Markers in EGFR-Mutated NSCLC
por: Barr, Martin P., et al.
Publicado: (2022)

Current Approaches in NSCLC Targeting K-RAS and EGFR
por: Aran, Veronica, et al.
Publicado: (2019)

Research Progress in Immunotherapy of NSCLC With EGFR-Sensitive Mutations
por: Yang, Yudie, et al.
Publicado: (2022)

Elevated phosphorylation of EGFR in NSCLC due to mutations in PTPRH
por: Swiatnicki, Matthew R., et al.
Publicado: (2022)

Heterogeneous distribution of EGFR mutation in NSCLC: Case report
por: Boukansa, Sara, et al.
Publicado: (2023)

Hope and Challenges: Immunotherapy in EGFR-Mutant NSCLC Patients
por: Yan, Dan
Publicado: (2023)

Prognostic value of plasma EGFR ctDNA in NSCLC patients treated with EGFR-TKIs
por: Zhang, Chengjuan, et al.
Publicado: (2017)

Dynamics of EGFR mutations in plasma recapitulates the clinical response to EGFR-TKIs in NSCLC patients
por: Xiong, Liwen, et al.
Publicado: (2017)

Adjuvant EGFR TKIs in NSCLC harboring EGFR mutations: looking for a consensus way
por: Attili, Ilaria, et al.
Publicado: (2020)

Combination of EGFR-TKIs with chemotherapy versus chemotherapy or EGFR-TKIs alone in advanced NSCLC patients with EGFR mutation
por: Wen, Miaomiao, et al.
Publicado: (2018)

Liquid biopsy uncovers distinct patterns of DNA methylation and copy number changes in NSCLC patients with different EGFR-TKI resistant mutations
por: Nguyen, Hoai-Nghia, et al.
Publicado: (2021)

Hypoxia-mediated translational activation of ITGB3 in breast cancer cells enhances TGF-β signaling and malignant features in vitro and in vivo
por: Sesé, Marta, et al.
Publicado: (2017)

ITGB3-mediated uptake of small extracellular vesicles facilitates intercellular communication in breast cancer cells
por: Fuentes, Pedro, et al.
Publicado: (2020)

Publisher Correction: ITGB3-mediated uptake of small extracellular vesicles facilitates intercellular communication in breast cancer cells
por: Fuentes, Pedro, et al.
Publicado: (2020)

Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR
por: Wang, Fen, et al.
Publicado: (2012)

Microwave ablation combined with EGFR-TKIs versus only EGFR-TKIs in advanced NSCLC patients with EGFR-sensitive mutations
por: Wei, Zhigang, et al.
Publicado: (2017)

miR-99a reveals two novel oncogenic proteins E2F2 and EMR2 and represses stemness in lung cancer
por: Feliciano, Andrea, et al.
Publicado: (2017)

Pooled analysis of clinical outcome for EGFR TKI-treated patients with EGFR mutation-positive NSCLC
por: Paz-Ares, Luis, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_3jqq9uvlmrvr4dj5qboib79ie1